Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)

The summary for the Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed): The purpose of this Notice of Funding Opportunity (NOFO) is to support investigators who have the interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (validated hits) for chemical optimization and bioassays for testing new analog compounds.Through this NOFO, NIH wishes to stimulate research in:Discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Eye Institute (NEI), and/or National Institute on Aging (NIA) andDiscovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms.Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes.

Federal Grant Title:	Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-27-081
Type of Funding:	Grant
CFDA Numbers:	93.242, 93.279, 93.866, 93.867
CFDA Descriptions:	Information not provided
Current Application Deadline:	March 5th, 2027
Original Application Deadline:	March 5th, 2027
Posted Date:	May 4th, 2026
Creation Date:	May 4th, 2026
Archive Date:	May 4th, 2027
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	May 4th, 2026

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Grant Announcement Contact: National Institute on Aging (NIA)
[email protected]
[email protected]
Similar Government Grants: • Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Data Processing...; • Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Int...; • Optimizing Treatment Strategies for Adult Attention-Deficit Hyperactivity Disorder (ADHD) ...; • National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of...; • National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of...; • Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...; • Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...; • Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
More Grants from the National Institutes of Health: • The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Lab...; • The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations ...; • NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed); • Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Data Processing...; • NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)